New study from University of California, Irvine and University of California, Santa Barbara researchers demonstrates improved retinal function and vascular integrity, supporting further investigation ...

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...

Please provide your email address to receive an email when new articles are posted on . Intravitreal injections have a large environmental impact, estimated to be around 210 million kg of CO 2 ...

BARCELONA, Spain — Adopting specific treatment regimens, reducing patient and staff travel, and limiting the use of unnecessary personal protective equipment can help improve the carbon footprint of ...

A low risk of adverse safety outcomes was observed in anti–vascular endothelial growth factor (VEGF) intravitreal injections performed in office-based and operating room settings, with a higher rate ...

If you're apprehensive about getting an intravitreal injection for age-related macular degeneration (AMD), you're not alone. Ophthalmologist Monika Fleckenstein, MD, explains the procedure, how it can ...

STOCKHOLM -- Two VEGF-targeting gene therapies for neovascular age-related macular degeneration (nAMD) substantially reduced treatment burden while preserving visual acuity, according to results ...

STOCKHOLM — Simple changes, like minimizing patient visits and reducing the use of nonsterile gloves, can make a big difference in the environmental impact of intravitreal injections without ...

Aflibercept 8mg (0.07mL of 114.3mg/mL); per vial; soln for oph intravitreal inj; preservative-free. A single-dose glass vial containing one Eylea HD 8 mg (0.07 mL of a 114.3 mg/mL solution); or A vial ...

What is behind the bilateral eye pain and failing vision affecting a 96-year-old woman with neovascular age-related macular degeneration (nAMD)? That's what ophthalmologists needed to determine when ...